CLINICAL TRIALS PROFILE FOR JEMPERLI
✉ Email this page to a colleague
All Clinical Trials for JEMPERLI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04926324 ↗ | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | Not yet recruiting | GlaxoSmithKline | Phase 1/Phase 2 | 2021-12-31 | This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures. |
| NCT04926324 ↗ | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | Not yet recruiting | Joseph Caster, Ph.D., M.D. | Phase 1/Phase 2 | 2021-12-31 | This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures. |
| NCT05526989 ↗ | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Not yet recruiting | GlaxoSmithKline | Phase 2 | 2022-09-15 | The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer. |
| NCT05526989 ↗ | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Not yet recruiting | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 2022-09-15 | The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer. |
| NCT05870761 ↗ | Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | Not yet recruiting | Casey Cosgrove | Phase 2 | 2023-06-30 | This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent). Niraparib belongs to a class of drugs called PARP inhibitors that prevent cancer cells from growing. Dostarlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Dostarlimab belongs to a class of drugs called PD-1 inhibitors that uses the patient's own immune system to treat cancer (immuno-therapy). Giving niraparib and dostarlimab may work better in treating patients with uterine serous carcinoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for JEMPERLI
Condition Name
Clinical Trial Locations for JEMPERLI
Trials by Country
Clinical Trial Progress for JEMPERLI
Clinical Trial Phase
Clinical Trial Sponsors for JEMPERLI
Sponsor Name
